Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Jun 8, 2026
Galmed Pharmaceuticals Ltd. has entered into a definitive agreement to acquire 100% of Colospan Ltd., an Israeli medical device company focused on colorectal surgical care. The total consideration is $4.5 million, comprised of $2.5 million in cash and $2.0 million in Galmed ordinary shares, with 7.5% held in escrow for 12 months. Colospan’s flagship product, the CG-100 Intraluminal Bypass Device, holds CE Marking in Europe and Breakthrough Device designation from the FDA.
Key figures
- Escrow Percentage
- 7.5
- Cash Consideration
- 2500000
- Lockup Period Months
- 24
- Stock Consideration
- 2000000
- Device Price
- 6000
- Target Market Size
- 6000000000
- Investment Commitment
- 6000000
- Pivotal Trial Enrolled
- 57
- Investment Period Months
- 24
- Pivotal Trial Randomized
- 39
- Pivotal Trial Enrollment Target
- 228
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.